Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CCR9 | P51686 | 7/20 | 0.59 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2530071 | 0.91 | LMNA (0.74) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL28518 | 0.89 | LMNA (0.80) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL28006 | 0.88 | LMNA (0.86) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL13146603 | 0.87 | LMNA (0.77) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL2531458 | 0.87 | LMNA (0.69) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL27979 | 0.86 | LMNA (0.83) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL2532380 | 0.85 | LMNA (0.71) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL3083603 | 0.85 | LMNA (0.75) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL13146484 | 0.85 | LMNA (0.60) | LMNAHTTTP53MAPTKMT2A | |
| SCHEMBL13146487 | 0.84 | LMNA (0.66) | LMNAHTTTP53MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | LMNA 4007/4885HTT 3097/4885TP53 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.